PCM
ROIV icon

Prelude Capital Management’s Roivant Sciences ROIV Stock Holding History

Prelude Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
113,104
+1,511
+1% +$44.7K 0.29% 77
2026
Q1 		$3.09M Sell
111,593
-8,922
-7% -$229K 0.24% 104
2025
Q4 		$2.62M Buy
120,515
+39,435
+49% +$778K 0.19% 115
2025
Q3 		$1.23M Sell
81,080
-83,700
-51% -$1.04M 0.1% 269
2025
Q2 		$1.86M Sell
164,780
-99,820
-38% -$1.08M 0.18% 144
2025
Q1 		$2.67M Buy
264,600
+19,660
+8% +$213K 0.2% 101
2024
Q4 		$2.9M Sell
244,940
-29,230
-11% -$346K 0.18% 115
2024
Q3 		$3.16M Buy
274,170
+11,892
+5% +$135K 0.19% 130
2024
Q2 		$2.77M Sell
262,278
-4,478
-2% -$49.1K 0.19% 140
2024
Q1 		$2.81M Buy
266,756
+248,555
+1,366% +$2.68M 0.15% 152
2023
Q4 		$204K Sell
18,201
-4,079
-18% -$39.8K 0.01% 936
2023
Q3 		$260K Sell
22,280
-27,020
-55% -$305K 0.02% 750
2023
Q2 		$497K Buy
49,300
+8,500
+21% +$76K 0.03% 464
2023
Q1 		$301K Buy
40,800
+19,700
+93% +$162K 0.02% 643
2022
Q4 		$169K Buy
+21,100
New +$117K 0.01% 1008

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Prelude Capital Management's ROIV Position: Q2 2026 in Review

Prelude Capital Management increased its Roivant Sciences (ROIV) stake by 1.4% in Q2 2026, buying an estimated $44.7K and bringing the position to 113,104 shares worth $4M. The position accounts for 0.29% of the portfolio, ranked #77.

Prelude Capital Management first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Prelude Capital Management held 113,104 shares of Roivant Sciences worth $4M as of Q2 2026.
  • Prelude Capital Management bought 1,511 Roivant Sciences shares in Q2 2026, an estimated $44.7K.
  • Roivant Sciences made up 0.29% of Prelude Capital Management's portfolio in Q2 2026, its #77 holding.
  • Prelude Capital Management first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.